ADCT Adc Therapeutics SA

  1. Stocks
  2. Healthcare
  3. NYSE: ADCT

Price (delayed)

$4.34

Market cap

$358.18M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.94

Enterprise value

$203.96M

adc therapeutics is a biotechnology company located in lausanne, vaud, switzerland.

Highlights
Adc Therapeutics's quick ratio has decreased by 8% YoY but it has increased by 6% from the previous quarter
Adc Therapeutics's equity has plunged by 174% from the previous quarter
The gross profit has plunged by 68% YoY and by 45% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://adctherapeutics.com
Peers: OMER OMGA

Key stats

What are the main financial stats of ADCT
Market
Shares outstanding
82.53M
Market cap
$358.18M
Enterprise value
$203.96M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
5.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.93
Earnings
Revenue
$69.56M
EBIT
-$154.62M
EBITDA
-$151.36M
Free cash flow
-$121.9M
Per share
EPS
-$2.94
Free cash flow per share
-$1.49
Book value per share
-$1.8
Revenue per share
$0.85
TBVPS
$4.34
Balance sheet
Total assets
$354.78M
Total liabilities
$503.03M
Debt
$124.38M
Equity
-$148.25M
Working capital
$268.62M
Liquidity
Debt to equity
-0.84
Current ratio
4.97
Quick ratio
4.49
Net debt/EBITDA
1.02
Margins
EBITDA margin
-217.6%
Gross margin
96.4%
Net margin
-345.1%
Operating margin
-238.6%
Efficiency
Return on assets
-53.4%
Return on equity
N/A
Return on invested capital
-88.7%
Return on capital employed
-53.9%
Return on sales
-222.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ADCT stock price

How has the Adc Therapeutics stock price performed over time
Intraday
-2.25%
1 week
-8.05%
1 month
-0.23%
1 year
121.43%
YTD
161.45%
QTD
-3.34%

Financial performance

How have Adc Therapeutics's revenue and profit performed over time
Revenue
$69.56M
Gross profit
$67.03M
Operating income
-$165.99M
Net income
-$240.05M
Gross margin
96.4%
Net margin
-345.1%
Adc Therapeutics's net margin has shrunk by 135% QoQ
ADCT's operating margin has dropped by 110% since the previous quarter
The gross profit has plunged by 68% YoY and by 45% from the previous quarter
The revenue has plunged by 67% YoY and by 43% from the previous quarter

Growth

What is Adc Therapeutics's growth rate over time

Valuation

What is Adc Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
5.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.93
Adc Therapeutics's EPS has decreased by 46% YoY and by 33% QoQ
Adc Therapeutics's equity has plunged by 174% from the previous quarter
The revenue has plunged by 67% YoY and by 43% from the previous quarter

Efficiency

How efficient is Adc Therapeutics business performance
Adc Therapeutics's return on sales has shrunk by 99% QoQ
The ROA has plunged by 80% YoY and by 44% from the previous quarter
The return on invested capital has declined by 33% year-on-year and by 24% since the previous quarter

Dividends

What is ADCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADCT.

Financial health

How did Adc Therapeutics financials performed over time
Adc Therapeutics's total assets is 29% less than its total liabilities
Adc Therapeutics's total assets has decreased by 28% YoY and by 24% from the previous quarter
ADCT's total liabilities is up by 22% year-on-year but it is down by 3.5% since the previous quarter
Adc Therapeutics's debt is 184% higher than its equity
Adc Therapeutics's equity has plunged by 174% from the previous quarter
The debt to equity has plunged by 157% YoY but it has soared by 63% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.